Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs NetEase Inc (NTES) Price & Performance

Citius Pharmaceuticals IncTrade
NetEase IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs NetEase Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while NetEase Inc trades at $124.3 (market cap $82.75B). The key difference: NetEase Inc is far larger — about 4135.4× Citius Pharmaceuticals Inc's market cap, and NetEase Inc pays a 2.36% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRNTES
Market Cap
$20.01M$82.75B
Sector
HealthMedia
52-Week High
$1.82$159.34
52-Week Low
$0.48$109.26
Enterprise Value
$16.23M$59.05B
Dividend Yield
2.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

NetEase Inc

NetEase (NTES) trades at $124.26, down 6.86% over 24 hours, with a P/E of 16.31 and P/S of 4.86. Recent earnings show a beat in Q1 2026 but misses in prior quarters. The company maintains strong profitability with a net income margin of 29.84% and ROE of 22.12%. Technical indicators signal a bullish trend, supported by positive analyst sentiment with 82% buy ratings.

The outlook for NTES is positive due to robust fundamentals and international expansion potential. Risks include earnings volatility and competitive pressures in the gaming sector. Upside is supported by a $0.72 dividend and strong cash flow generation, though investors should monitor quarterly performance against expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About NetEase Inc

NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).

Read more on NTES